Journal: Molecular Therapy Oncology

Article Title: AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation

doi: 10.1016/j.omton.2026.201216

Figure Lengend Snippet: Differential transduction of human GBM cell lines with AAV vector serotypes (A) Representative images of U-87 MG and patient-derived cell lines transduced with AAV1, 2, 1/2, 6, and 6.2 expressing eGFP and pBS control-treated control. Green, GFP expression; magenta, EdU staining; blue, Hoechst staining. Scale bars, 100 μm. (B) Quantitation of the transduction efficiency for all serotypes in each cell line as determined by GFP expression. All data presented as mean (SD), n = 3 biological replicates.

Article Snippet: The commercial human GBM cell line U-87 MG (ATCC) was plated at 5,000 cells per well in Eagle’s minimal essential medium (EMEM) (ATCC, 30–2003) supplemented with 10% FBS (Gibco, 10091148) and Penicillin-Streptomycin-Glutamine (Gibco, 10378016).

Techniques: Transduction, Plasmid Preparation, Derivative Assay, Expressing, Control, Staining, Quantitation Assay

Journal: Molecular Therapy Oncology

Article Title: AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation

doi: 10.1016/j.omton.2026.201216

Figure Lengend Snippet: AAV transduced CD44-positive cell populations with greater efficiency (A) Transduction efficiency of AAV1, 2, 1/2, 6, and 6.2 in CD44-positive and -negative cell populations. Two-way ANOVA showed no significant interaction between the effects of AAV serotype and CD44 expression on transduction efficiency in all cell lines. There was a significant main effect of CD44 expression in U-87 MG ( p = 0.007), case 1 ( p = 0.0003), and case 4 ( p = 0.010) but no statistical significance was found following Sidak’s multiple comparisons test. (B) CD44 expression in human GBM cell lines following AAV treatment. (C) Proliferation of the CD44-positive cell population normalized to values from NTC-treated control. Treatments were compared against their respective pBS-treated control. All data presented as mean (SD), n = 3 biological replicates. Statistical significance is shown as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: The commercial human GBM cell line U-87 MG (ATCC) was plated at 5,000 cells per well in Eagle’s minimal essential medium (EMEM) (ATCC, 30–2003) supplemented with 10% FBS (Gibco, 10091148) and Penicillin-Streptomycin-Glutamine (Gibco, 10378016).

Techniques: Transduction, Expressing, Control

Journal: Molecular Therapy Oncology

Article Title: AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation

doi: 10.1016/j.omton.2026.201216

Figure Lengend Snippet: Reductions in cell number and proliferation following AAV treatment persisted in the absence of transgene expression (A) Representative images of U-87 MG, cases 2 and 5 transduced with AAV expressing eGFP or no transgene, along with their respective pBS controls. Green, GFP expression; magenta, EdU staining; blue, Hoechst staining. Scale bars, 100 μm. (B) Total cell number and (C) cell proliferation in the 24 h prior to fixation, normalized to values from NTC-treated control. Treatments were compared against their respective pBS-treated control. All data presented as mean (SD), n = 3 biological replicates. Statistical significance is shown as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: The commercial human GBM cell line U-87 MG (ATCC) was plated at 5,000 cells per well in Eagle’s minimal essential medium (EMEM) (ATCC, 30–2003) supplemented with 10% FBS (Gibco, 10091148) and Penicillin-Streptomycin-Glutamine (Gibco, 10378016).

Techniques: Expressing, Transduction, Staining, Control

Journal: Molecular Therapy Oncology

Article Title: AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation

doi: 10.1016/j.omton.2026.201216

Figure Lengend Snippet: AAV treatment induced cell-cycle arrest at G1 in cases 2 and 5 but not U-87 MG (A) Cumulative cytotoxicity was evaluated by LDH release assay 4 days following AAV treatment, normalized to the maximal LDH release from the Triton X-100 control. No statistical significance was detected. (B) Percentage of cells in each cell cycle phase (G0/G1, S, and G2/M) were quantified via DNA content profiling (see also ). All data presented as mean (SD), n = 3 biological replicates. Treatments were compared against their respective pBS-treated control. Statistical significance is shown as G0/G1 phases: ∗∗∗∗ p < 0.0001; S phase: † p < 0.05; G2/M phases: # p < 0.05, ### p < 0.001.

Article Snippet: The commercial human GBM cell line U-87 MG (ATCC) was plated at 5,000 cells per well in Eagle’s minimal essential medium (EMEM) (ATCC, 30–2003) supplemented with 10% FBS (Gibco, 10091148) and Penicillin-Streptomycin-Glutamine (Gibco, 10378016).

Techniques: Lactate Dehydrogenase Assay, Control